TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an update.
Cardiol Therapeutics Inc. released its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a significant decrease in cash and cash equivalents from $30.6 million at the end of 2024 to $11.6 million as of September 30, 2025. The financial results indicate a net loss of $26.6 million for the nine-month period, reflecting ongoing challenges in managing operational expenses and research and development costs. This financial performance highlights the company’s need to secure additional funding or improve operational efficiencies to sustain its development programs.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.
Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a pharmaceutical company based in Oakville, Ontario, Canada. The company focuses on developing innovative therapies for inflammatory heart diseases. Cardiol’s primary products and services are centered around the research and development of anti-inflammatory therapies, with a particular emphasis on heart failure and myocarditis.
Average Trading Volume: 153,636
Technical Sentiment Signal: Sell
Current Market Cap: C$144.4M
See more insights into CRDL stock on TipRanks’ Stock Analysis page.